A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

418

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: Guselkumab Dose 1
DRUG: Guselkumab Dose 2
DRUG: Guselkumab Dose 3
OTHER: Placebo

Sponsor

Janssen Research & Development, LLC